Drug · DIN 02264218
TEVA-RISPERIDONE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 26, 2022; first marketed July 5, 2006.
- Drug Identification Number (DIN)
- 02264218
- Company (DIN owner)
- Teva Canada LimitedToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Risperidone N05AX08
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISPERIDONE | 2 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 26, 2022: NOC 29316Abbreviated New Drug Submission (ANDS) · Administrative: Licensing Agreement Between Two Companies
- November 28, 2012: NOC 13910Abbreviated New Drug Submission (ANDS) · Manufacturer and product name change
- July 5, 2006: NOC 8113Abbreviated New Drug Submission (ANDS)
Other DINs named TEVA-RISPERIDONE
- DIN 02264196 · Marketed
- DIN 02264226 · Marketed
- DIN 02264234 · Marketed
- DIN 02282690 · Marketed
- DIN 02264188 · Dormant